SP-141|cas:1253491-42-7|西域试剂

SP-141,98.66%

产品编号：Bellancom-110182| CAS NO：1253491-42-7| 分子式：C₂₂H₁₆N₂O| 分子量：324.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-110182	￥1000.00	杭州北京（现货）
Bellancom-110182	￥1600.00	杭州北京（现货）
Bellancom-110182	￥3500.00	杭州北京（现货）
Bellancom-110182	￥5900.00	杭州北京（现货）
Bellancom-110182	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SP-141

产品介绍

SP-141 是一种特异性的 MDM2 抑制剂。SP-141 促进 MDM2 自泛素化和降解。SP-141 可用于胰腺癌和乳腺癌的研究。

生物活性

SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells.

体外研究

SP-141 (0.01-10 μM; 72 hours) inhibits human pancreatic cancer cell growth with IC₅₀ values of less than 0.5 μM (0.38-0.50 μM) in a p53-independent manner. The IMR90 cells are much less sensitive to SP141 than the pancreatic cancer cells, suggesting that SP141 has a selective cytotoxicity for cancer cells.
SP141 induces MDM2 auto-ubiquitination and proteasomal degradation in both HPAC and Panc-1 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HPAC, Panc-1, AsPC-1, and Mia-Paca-2 pancreatic cancer cell lines. Human primary fibroblasts (IMR90)
Concentration:	0.01, 0.1, 1, and 10 μM
Incubation Time:	72 hours
Result:	IC₅₀s of 0.38, 0.50, 0.36, 0.41, and 13.22 μM for HPAC, Panc-1, AsPC-1, Mia-Paca-2, and IMR90, respectively.

Western Blot Analysis

Cell Line:	HPAC and Panc-1 cells
Concentration:	0.5 μM
Incubation Time:	120 minutes
Result:	Reduced the MDM2 protein levels. Increased the degradation rate of the MDM2 protein in the presence of Cycloheximide (15 μg/mL).

体内研究
(In Vivo)

SP-141 (40 mg/kg; administered by i.p. injection; 5 d/wk for about three weeks) suppresses pancreatic tumor growth in both xenograft and orthotopic mouse models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing Panc-1 xenograft tumors
Dosage:	40 mg/kg
Administration:	Administered by i.p. injection; 5 d/wk for about three weeks
Result:	Significantly suppressed the growth of pancreatic xenograft tumors. On Day 18, the tumor volume in the treated group was reduced by 75% compared with that in the control group. There were no significant differences in the body weight compared with the control group.

体内研究

SP-141 (40 mg/kg; administered by i.p. injection; 5 d/wk for about three weeks) suppresses pancreatic tumor growth in both xenograft and orthotopic mouse models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing Panc-1 xenograft tumors
Dosage:	40 mg/kg
Administration:	Administered by i.p. injection; 5 d/wk for about three weeks
Result:	Significantly suppressed the growth of pancreatic xenograft tumors. On Day 18, the tumor volume in the treated group was reduced by 75% compared with that in the control group. There were no significant differences in the body weight compared with the control group.

体内研究

SP-141 (40 mg/kg; administered by i.p. injection; 5 d/wk for about three weeks) suppresses pancreatic tumor growth in both xenograft and orthotopic mouse models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing Panc-1 xenograft tumors
Dosage:	40 mg/kg
Administration:	Administered by i.p. injection; 5 d/wk for about three weeks
Result:	Significantly suppressed the growth of pancreatic xenograft tumors. On Day 18, the tumor volume in the treated group was reduced by 75% compared with that in the control group. There were no significant differences in the body weight compared with the control group.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (385.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0828 mL	15.4140 mL	30.8280 mL
5 mM	0.6166 mL	3.0828 mL	6.1656 mL
10 mM	0.3083 mL	1.5414 mL	3.0828 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.41 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.41 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.41 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.41 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。